Somewhat Positive Media Coverage Somewhat Unlikely to Impact PAVmed (PAVM) Stock Price

News coverage about PAVmed (NASDAQ:PAVM) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PAVmed earned a daily sentiment score of 0.02 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.4318078519138 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

PAVmed (NASDAQ:PAVM) traded up $0.11 during mid-day trading on Monday, hitting $1.62. 26,600 shares of the company traded hands, compared to its average volume of 77,903. The company has a debt-to-equity ratio of -0.26, a quick ratio of 0.42 and a current ratio of 0.42. PAVmed has a 1-year low of $1.35 and a 1-year high of $9.31. The firm has a market cap of $27.87, a price-to-earnings ratio of -1.74 and a beta of -3.15.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact PAVmed (PAVM) Stock Price” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at

PAVmed Company Profile

PAVmed Inc operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device.

Insider Buying and Selling by Quarter for PAVmed (NASDAQ:PAVM)

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply